44-136

antibody from Invitrogen Antibodies

Targeting: APP AD1

ELISA

Immunohistochemistry

Radioimmunoassay

Antibody data

Submit

Validation data

Product number: 44-136 - Provider product page
Provider: Invitrogen Antibodies
Product name: beta Amyloid (1-40) Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: No significant cross-reactivity to beta-Amyloid 42 has been observed. Previous lots of this antibody recognized the sequence of beta-Amyloid [1-40] in the region from amino acids 15-30. No blocking activity was observed with beta-Amyloid [1-12] whereas the peptides beta-Amyloid [14-35], beta-Amyloid [15-28], beta-Amyloid [17-30] and Beta-Amyloid [1-40] were all able to block antibody activity.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20°C

APP protein structure - 44-136 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Upper line ( a - d ): Serial confocal microscopic changes of double-immunolabeled vessels (green, smooth muscle actin; red, amyloid). Lower line ( e - h ): Confocal microscopic findings represent negative controls without primary antibody for Abeta. a, b, Leptomeningeal vessel in a 15-month-old mouse shows small amyloid deposition and focal loss of smooth muscle cells at the site of cerebrovascular amyloid; c, d, In a 23-month-old mouse, smooth muscle cells are lost, and a thick sheet of amyloid covers the wall of a leptomeningeal vessel. e-f, Photos of the negative controls for Abeta (each section adjacent to a, b, c, d, respectively) show only a faint background stain in the vessel walls. Scale bar: 50 um.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Representative images of cerebral micro-hemorrhage findings (a, b, Perls''s Berlin blue stain with Nuclear Fast Red (Kernechtrot stain solution)); b, d, double-labeled for amyloid (brown) and hemosiderin (blue)). ( a ) Clusters of hemosiderin staining are shown in the brain parenchyma (cortex at 1.35 mm behind Bregma). ( b ) In an adjacent section to a, some of them are in contact with amyloid-beta (Abeta)-positive vessels. ( c ) Localized hemosiderin shown around the vessel wall (cortex at 0.85 mm behind Bregma). ( d ) In an adjacent section to c, localized bleeding to amyloid-laden vessels is shown. Scale bars indicate 10 um.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Representative images of cerebral amyloid angiopathy (CAA) in a Tg2576 mouse (aged 23 months old). Pan-Abeta immunostained sections show significant CAA in the cortex at 1.08 mm behind Bregma (a: arrowheads) and mild to moderate CAA (b: arrowheads) in the hippocampus at 1.33 mm behind Bregma. Arrows show senile plaques in the hippocampus ( b ). Vessel with a thin rim of amyloid in the vessel wall (c; severity grade, 1); vascular amyloid with amyloid infiltrating the surrounding neuropil (d; severity grade, 2); dysphoric amyloid with amyloid deposition within the vessel wall and with a thick and complete amyloid coat around the vessel wall (e; severity grade, 3). Scale bars indicate 100 um ( a , b ) and 10 um ( c - e ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: ijms-21-02295-sch001_Scheme A1 Scheme A1 Semi-automatic measurement of senile plaques in the regions of interest (cortex and the hippocampus). Upper line: Measurement of the area of the section: (1) Filling of the section ( a ) with red color ( b ); (2) dichotomization of color into black and white using a semiautomatic method with an appropriate color threshold ( c ). Lower line: Measurement of the total area of the senile plaque: (1) digital stripping of Abeta-stained lesions located out of the regions of interest ( d ); (2) change of color of the remaining Abeta-stained area to red using manual calibration with an appropriate color threshold ( e ); (3) dichotomization of color to black (Abeta-stained lesions in regions of interest) and white (other) using a semiautomatic method with an appropriate color threshold ( f ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Single intravenous injection of SST-scFv8D3 increases brain levels of neprilysin but has no detectable effect on Abeta levels. (A). Comparison of neprilysin expression in the brain of wild-type mice (n=4), eight-months old APPswe (n=7) and fourteen-months old APPswe mice (n=4). APPswe mice exhibit a significant reduction in neprilysin levels compared to wild-type. A significant age-dependent decline in neprilysin protein levels is detected between the APPswe groups. (B). Schematic representation of the first therapeutic study with SST-scFv8D3. Fourteen-month old transgenic mice harbouring the Swedish mutation in APP (APPswe) injected intravenously with 2 mg/kg of SST-scFv8D3 (n=4) or PBS (n=4) as a negative control. Mice euthanized 24 h post injection by perfusion with physiological saline. (C). Significant increase in the levels of neprilysin in the membrane fraction (TBS-Triton soluble) of the brain of the treatment group. No differences detected in the levels of Abeta40 and Abeta42, neither in the soluble pool (D), nor in the membrane fraction (E) between SST-scFv8D3 treated group and the controls. Results are presented as mean +-SD. One-way ANOVA followed by Tukey's post hoc test (A) and unpaired t-test (C-E) were applied to measure the presence of statistically significant differences in the results. A significant p-value is defined as: >0.5 (ns),